SEARCH

SEARCH BY CITATION

References

  • 1
    Gines P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W, Liard JF, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998; 28:851864.MEDLINE
  • 2
    Gines P, Jimenez W. Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. J Hepatol 1996; 24:506512.MEDLINE
  • 3
    Arroyo V, Clària J, Saló J, Jiménez W. Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994; 14:4458.MEDLINE
  • 4
    Salerno F, DelBo A, Maggi A, Marabini M, Maffi M, Borroni GM, Moser P. Vasopressin release and water metabolism in patients with cirrhosis. J Hepatol 1994; 21:822830.MEDLINE
  • 5
    Camps J, Sola J, Arroyo V, Perez-Ayuso RM, Gaya J, Rivera F, Rodes J. Temporal relationship between the impairment of free water excretion and antidiuretic hormone hypersecretion in rats with experimental cirrhosis. Gastroenterology 1987; 93:498505.MEDLINE
  • 6
    Bosch-Marce M, Jimenez W, Angeli P, Leivas A, Claria J, Graziotto A, Arroyo V, et al. Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention. Gastroenterology 1995; 109:217223.MEDLINE
  • 7
    Pérez-Ayuso RM, Arroyo V, Camps J, Jiménez W, Rodamilans M, Rimola A, Gaya J, et al. Effect of demeclocycline on renal function and urinary prostaglandin E2 and kallikrein in hyponatremic cirrhotics. Nephron 1984; 36:3037.MEDLINE
  • 8
    Reece PA, Sedman AJ, Rose S, Wright DS, Dawkins R, Rajagopalan R. Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J Clin Pharmacol 1994; 34:11261132.MEDLINE
  • 9
    Gadano A, Moreau R, Pessione F, Trombino C, Giuily N, Sinnassamy P, Valla D, et al. Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol 2000; 32:3842.MEDLINE
  • 10
    Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992; 105:787791.MEDLINE
  • 11
    Ohnishi A, Orita Y, Okahara R, Fujihara H, Inoue T, Yamamura Y, Yabuuchi Y, et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993; 92:26532659.MEDLINE
  • 12
    Inoue T, Ohnishi A, Matsuo A, Kawai B, Kunihiro N, Tada Y, Koizumi F, et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998; 63:561570.MEDLINE
  • 13
    Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, et al. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 1996; 98:27292738.MEDLINE
  • 14
    Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, et al. VPA-985, a non peptide orally active and selective vasopressin V2 receptor antagonist. In: ZinggHH, ed. Vasopressin and Oxytocin. New York: Plenum Press, 1998; 439443.
  • 15
    Chan PS, Lai F, Ru X, Shepherd C, Bailey T, Li PJ, Dusza JP, et al. Pharmacological characterization of VPA-985, a potent non peptidic orally-active and selective vasopressin (AVP) V2 receptor antagonist. J Am Soc Nephrol 1998; 9(Suppl):16A.
  • 16
    Muralidharan G, Meng X, DeCleene SA, Cevallos WH, Fruncillo R, Hicks D, Orczyk GP. Pharmacokinetics and pharmacodynamics of a novel vasopressin receptor antagonist, VPA-985 in healthy subjects. Clin Pharmacol Ther 1999; 65:189.
  • 17
    Abraham WT, Oren RM, Crisman TS, Robertson AD, Shaker S, Lowes BD, Panther L, et al. Effects of an oral, non-peptide, selective V2 receptor vasopressin antagonist in patients with chronic heart failure. J Am Coll Cardiol 1997; 29(Suppl):169A.
  • 18
    Martin PY, Abraham WT, Lieming X, Olson BR, Oren RM, Ohara M, Schrier RW. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999; 10:21652170.MEDLINE
  • 19
    Bichet DG, Rémillard G, Madore F, Mallié JP, Arthus MF, Deslauriers N, Drouin M, et al. Correction of hyponatremia by a single oral dose of 75 mg of the non-peptide vasopressin V2 antagonist VPA-985 in hyponatremic patients receiving carbamazepine or oxycarbamazepine. J Am Soc Nephrol 1999; 10:119A.
  • 20
    Ginès P, Fernandez-Esparrach G, Arroyo V, Rodès J. Pathogenesis of ascites in cirrhosis. Semin Liver Dis 1997; 17:175189.MEDLINE
  • 21
    Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann Intern Med 1997; 126:5762.MEDLINE
  • 22
    Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 1998; 449:439443.MEDLINE
  • 23
    Patat A, Ellis-Grosse EJ, Orczyk GP, Gandon JM. Pharmacodynamic effects of a novel, non-peptide, V2 receptor antagonist, VPA-985, given with hydrochlorothiazide. Clin Pharmacol Ther 2000; 67:110.
  • 24
    Swan SK, Lambvrecht LJ, Orczyk GP, Ellis-Grosse EJ. Interaction between VPA-985, an ADH (V2) antagonist, and furosemide. J Am Soc Nephrol 1999; 10:124A.
  • 25
    Bosch-Marce M, Poo JL, Jimenez W, Bordas N, Leivas A, Morales-Ruiz M, Munoz RM, et al. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention. J Pharmacol Exp Ther 1999; 289:194201.MEDLINE
  • 26
    Jimenez W, Serradeil-Le Gal C, Ros J, Cano C, Cejudo P, Morales-Ruiz M, Arroyo V, et al. Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J Pharmacol Exp Ther 2000; 295:8390.MEDLINE
  • 27
    Decaux G, Hannotier P, Penninckx R, Soupart A, Djian J. Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, VPA-985. J Am Soc Nephrol 1999; 10:120A.
  • 28
    Gerbes AL, Guelberg V, Decaux G, Gross P, Massien C, Djian J. VPA-985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double blind placebo controlled multicenter trial. Hepatology 1999; 30(Suppl):419A.
  • 29
    Gross P, Decaux G, Gerbes A, Djian J. Treatment of hyponatremia with VPA-985. J Am Soc Nephrol 1999; 10:121A.
  • 30
    Wong F, Blei AT, Blendis LM, Robertson AD, Thuluvath PT. The effects of VPA-985, a vasopressin receptor antagonist, on water metabolism in patients with hyponatremia: a multicenter randomized placebo controlled trial. Gastroenterology 2000; 118(Suppl 2):A980A981.
  • 31
    Reznick RK, Langer B, Taylor BR, Seif S, Blendis LM. Hyponatremia and arginine vasopressin secretion in patients with refractory hepatic ascites undergoing peritoneovenous shunting. Gastroenterology 1983; 84:713718.MEDLINE
  • 32
    Lacour C, Galindo G, Canals F, Segondy D, Cazaubon C, Serradeil-Le Gal C, Roccon A, et al. Aquaretic and hormonal effects of a vasopressin V(2) receptor antagonist after acute and long-term treatment in rats. Eur J Pharmacol 2000; 394:131138.MEDLINE
  • 33
    Gross P, Reimann D, Henschkowski J, Damian M. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol 2001; 12:S10S14.MEDLINE
  • 34
    Thibonnier M, Conary DM, Preston JA, Wilkins PL, Berti-Mattera LN, Mattera R: Molecular pharmacology of human vasopressin receptors. In: ZinggHH, ed. Vasopressin and Oxytocin. New York: Plenum Press, 1998; 251276.